By continuing to use the site you agree to our Privacy & Cookies policy

Your browser seems to have cookies disabled. For the best experience of this website, please enable cookies in your browser.


Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.


Room temperature version of coagulation factor

Novo Nordisk UK has announced that NovoSeven – its recombinant activated factor VII product available for the treatment of bleeding episodes in people with haemophilia with inhibitors – is now available as a room temperature stable formulation from today onwards. This replaces the previous formulation, which required refrigeration.

This new formulation, which is stable at temperatures up to 25°C, enables patients to administer treatment effectively and quickly after the onset of bleeding in any setting.

Have your say

You must sign in to make a comment.

Related Jobs

Sign in to see the latest jobs relevant to you!